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ABSTRACT
Although several tools facilitating in silico drug de-
sign are available, their results are usually difficult
to integrate with publicly available information or re-
quire further processing to be fully exploited. The
rational design of multi-target ligands (polypharma-
cology) and the repositioning of known drugs to-
wards unmet therapeutic needs (drug repurposing)
have raised increasing attention in drug discovery,
although they usually require careful planning of tai-
lored drug design strategies. Computational tools
and data-driven approaches can help to reveal novel
valuable opportunities in these contexts, as they en-
able to efficiently mine publicly available chemical,
biological, clinical, and disease-related data. Based
on these premises, we developed LigAdvisor, a data-
driven webserver which integrates information re-
ported in DrugBank, Protein Data Bank, UniProt, Clin-
ical Trials and Therapeutic Target Database into an
intuitive platform, to facilitate drug discovery tasks
as drug repurposing, polypharmacology, target fish-
ing and profiling. As designed, LigAdvisor enables
easy integration of similarity estimation results with
clinical data, thereby allowing a more efficient ex-
ploitation of information in different drug discovery
contexts. Users can also develop customizable drug
design tasks on their own molecules, by means of
ligand- and target-based search modes, and down-




Drug discovery traditionally relied on the identification of
compounds that selectively hit a single biological target of
interest, while limiting adverse reactions. However, it is cur-
rently established that drugs very often exert their effects
through the simultaneous modulation of complex networks
of targets. The possibility of modulating selected combina-
tions of targets involved in the physiopathology of multi-
factorial diseases to achieve improved therapeutic effects
paved the way to polypharmacology (1), which nowadays
is primarily pursued through in silico approaches (2). Simi-
larly, repositioning approved drugs and clinically safe can-
didates that did not meet their primary expectations to-
wards unmet therapeutic needs represents an opportunity
that has recently gained considerable interest in drug dis-
covery (3–5). Indeed, such an approach makes it possible to
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sensibly reduce risks and costs that can usually be associated
to the drug discovery process, although repurposing oppor-
tunities have mostly been discovered through retrospective
analyses (3). In this context, computational tools and web
platforms facilitating these drug discovery tasks have flour-
ished in recent times, by taking advantage of data-driven
approaches and big data (6–12). Common drug reposition-
ing strategies include the identification of novel potential
targets by means of their similarity with drugs already in
use in therapeutic regimens for a specific disease. Strategies
based on in silico structure-based approaches (e.g., dock-
ing (13)), have also being pursued for the same purposes,
although the integration of different methods is expected to
provide improved drug repurposing predictions (14).
In a recent study (15), we performed extensive in silico
investigations within the Protein Data Bank (PDB) (16),
with the aim of identifying promising target combinations
for polypharmacology. The results of this study allowed us
to conclude that ligands reported within the PDB represent
a reliable source of structural and biological information
for multi-target drug design and repurposing (15). More-
over, we also discussed on how the chemical space covered
by crystallographic ligands in the PDB is significantly less
populated by pan-assay interference (PAINS) and poten-
tial false positive compounds, even if it is lower in size with
respect to other bioactivity-oriented databases (e.g., Pub-
Chem (17) and ChEMBL (18), these aspects being of crucial
interest in target-driven drug discovery.
Based on these premises, we developed LigAdvisor
(https://ligadvisor.unimore.it/), a webserver that allows
users to perform 2D fingerprint-based similarity analyses
on databases of compounds curated from DrugBank (19)
and PDB (16), and to integrate the results with data re-
ported in clinical trials (https://clinicaltrials.gov/), UniProt
(20) and TTD (Therapeutic Target Database) (21). Indeed,
LigAdvisor is primarily designed to assist in the identifi-
cation of novel potential targets for already known drugs
or clinical candidates, by means of their similarity with re-
ported crystallographic ligands, and vice versa. This infor-
mation is expected to help in the identification of potential
biological activities for a (set of) ligand(s) of interest on a
wider range of targets, compared to other drug repurposing
or multi-target ligand webservers (e.g., 8,9,12), thereby sig-
nificantly improving the repositioning opportunities. More-
over, it provides integration of disease information and in-
volvement in shared biological pathways for a given pair of
targets, which is an essential aspect for polypharmacology
design. A comparison of the potentialities offered by Lig-
Advisor with respect to other currently available drug re-
purposing and polypharmacology related websites is pro-
vided in the ‘LigAdvisor and current webservers for drug
repurposing and polypharmacology’ section (see below).
Another important strength of LigAdvisor is the pos-
sibility to link similarity data with information available
from PDB crystallographic compounds and their respec-
tive protein-ligand complexes. Indeed, this information can
facilitate the interpretation of the mode of binding and
structure-activity relationships across one or more targets
for a query molecule, which is a key advantage in polyphar-
macology and drug discovery in general. Remarkably, Lig-
Advisor allows the integration of results of clinical trial in-
formation on the same or similar compounds, if present.
Moreover, LigAdvisor can be used to analyse fully cus-
tomizable molecular structures to identify potential molec-
ular targets of already synthesized libraries of chemical
compounds, which can be easily uploaded by users for the
analyses. Indeed, these compounds are of great value for
drug discovery, as they help to circumvent potential feasibil-
ity issues often encountered when synthesizing novel chem-
ical scaffolds (22).
LigAdvisor is designed to also help non-expert in the field
of in silico drug discovery in the identification of poten-
tial multi-target activities and repurposing opportunities of
their compounds of interest. Indeed, our website features a
fast and intuitive interface that does not require any pro-
gramming knowledge, and allows users to download search
results as easy-to-interpret graphs and tables. At the same
time, LigAdvisor results can be post-processed by high-end
users via more sophisticated refinement and rescoring al-
gorithms, for example, through further in silico analyses
(e.g., docking or free energy evaluations), since the crys-
tallographic compounds in the database have already been
reported in complex with their primary targets. For exam-
ple, these analyses may help in the identification of suitable
combination of targets and their respective crystallographic
conformations for further structure-based investigations, in
both multi-target drug design and integrated in silico drug
repurposing campaigns (13–15,23).
Another key strength of LigAdvisor is the possibility
to identify targets potentially involved in common and/or
similar therapeutic indications by means of the similarity
between their ligands, as well as structurally similar com-
pounds for a selected target pair of interests, through unique
multi-query search runs.
LigAdvisor can be queried through different search types,
which can be either ligand- or target-oriented, to enable
a more effective exploitation of the advantages of both
approaches. Importantly, another strength is the imple-
mentation of additional query functionality that allows re-
searchers to combine LigAdvisor results with searches on
clinical trials data. To the best of our knowledge, these types
of database explorations have never been implemented to-
gether into drug design webservers. The possibility to in-
terrogate LigAdvisor through such multi-query searches is
expected to significantly facilitate and speed-up drug repur-
posing, target fishing and polypharmacology tasks.
In this manuscript, we will describe the curated datasets,
the information employed in the LigAdvisor webserver, and
the construction of the related user-friendly interfaces. We
will also illustrate the different types of search implemented
into the webserver, and how they can be used in multiple
drug design tasks, with particular focus on polypharma-
cology, target fishing and drug repurposing tasks. Finally,
we will discuss selected case studies to better highlight the
potential offered by the LigAdvisor webserver in different
drug design and discovery contexts.
MATERIALS AND METHODS
Molecular datasets preparation
Two different datasets of compounds curated from Pro-
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used as the basis for the searches implemented in LigAdvi-
sor. In particular, ligands reported in crystallographic com-
plexes were first downloaded from the Protein Data Bank
(33 391 compounds, accessed on 25 November 2020). Then,
compounds were filtered to retain ligands with 5–55 heavy
atoms. Moreover, compounds corresponding to small pep-
tides and crystallographic solvents were also removed, lead-
ing to a final database of 28 415 unique small molecule
entries, crystallized across 237 374 different protein com-
ponent chains. Chain-specific information was retained in
this phase of dataset preparation, as ligands can potentially
adopt different conformation, protonation and tautomer-
ization states across different chains, also within the same
protein complex. At the same time, ligands can also bind
only to specific component chains in multi-protein crys-
tallographic complexes. For each PDB ligand, information
about crystal complexes were downloaded from PDB and
matched with their respective molecular targets through the
UniProt ID (20).
The overall publicly available dataset of DrugBank was
downloaded and directly employed in the analyses, as it con-
tains highly characterized ligands (10 767 compounds, ac-
cessed on 25 November 2020).
The Pandas Python library (version 1.1.3) available in
Anaconda (https://anaconda.com/, version 2-2-4.0) was
used to cross-reference PDB-related information to data on
targets, and their associated diseases and pathways reported
in the UniProt database (accessed on 25 November 2020)
and TTD (accessed on 14 April 2021) (21), respectively.
Moreover, the PubChemPy library (https://github.com/
mcs07/PubChemPy, version 1.0.4, accessed on 25 Novem-
ber 2020) was used to programmatically retrieve from the
PubChem database (17) molecules synonyms and identifiers
across several established online platforms and databases
(e.g., PubChem, PDB, DrugBank, ChEMBL and others), to
be associated with clinical data (16–19). Additional brand
names of drugs and candidates, as well as their associa-
tions, were extracted from the FDA website (https://www.
accessdata.fda.gov/scripts/cder/daf/index.cfm, accessed on
25 November 2020), and DrugBank (https://go.drugbank.
com/releases/latest#open-data, accessed on 25 November
2020) to further facilitate their association with clinical
data.
Clinical data preparation
Data related to clinical trials was first downloaded from
(https://clinicaltrials.gov/, accessed on 25 November 2020)
and processed by using the Pandas Python library (ver-
sion 1.1.3) available in Anaconda. This allowed to extract
studies identifiers and information about their status, phase,
type, assessed therapeutic condition and outcome descrip-
tion. Then, a KNIME (version 4.3.1) (24) workflow was
devised to match drugs and candidate synonyms, with in-
formation reported in the pre-processed clinical data. This
procedure allowed us to associate each clinical trial with
the drug identifiers and candidate compounds on other
databases, both alone and in combination, for a total of
359 341 records.
Similarity estimations
Similarities between ligands are evaluated by means of
MACCS and Morgan (ECFP) fingerprints, implemented in
the RDKit Python libraries (https://www.rdkit.org, release
2020-9, accessed on 22 February 2020). Default parameters
were used for the generation of MACCS fingerprints, while
a bit length of 1024 and a radius equal to 2 were employed
for the Morgan fingerprints (ECFP4). The 2D similarity
between ligands was evaluated in terms of the Tanimoto
score (25). Pairs of compounds with similarity scores below
the commonly accepted thresholds of 0.8 (MACCS) or 0.3
(Morgan) were discarded (26). Similarities between Drug-
Bank and PDB ligands, which currently cover >2.5 million
records, are pre-computed to enable fast retrieving of re-
sults from the webserver. Moreover, the obtained similari-
ties allowed to identify 13 million target associations, which
can be investigated for multi-target drug design. Statistics
related to pre-calculated similarities and target combina-
tions are reported in Figure 1. Further database updates are
planned throughout the year, as more data becomes avail-
able, to increase usability of LigAdvisor for drug design.
Web implementation
The database used in the webserver was generated us-
ing PostgreSQL (https://www.postgresql.org/, version 12.6),
while all web interfaces were developed using Angular
(https://angular.io/, version 9.1.0).
The server-side application was developed using Python
(https://www.python.org/download/releases/2.6/, version
2.6.12) with Flask (https://flask.palletsprojects.com/, ver-
sion 1.1.2). The LigAdvisor server is hosted on a Linux
server (Ubuntu 20.04) equipped with Intel Xeon processors
(model E5-2603). To handle the requests on LigAdvisor
server Nginx (https://nginx.org/en/, version 1.18) with Gu-
nicorn (https://gunicorn.org/) is used. The LigAdvisor web
application was successfully tested on various platforms,
including Windows and Mac OS.
THE LIGADVISOR WEBSERVER
The LigAdvisor web platform relies on manually curated
databases of ligands extracted from DrugBank, Protein
Data Bank, and data related to clinical trials and target-
disease associations. Together, these data are expected to
assist users in drug design operations and suggest, e.g. po-
tential targets for known molecules, ad hoc multi-target ac-
tivities, and drug repurposing.
As designed, LigAdvisor allows users to perform single-
query or multi-query searches, as described below. Key ex-
amples and step-by-step instructions on how to perform
these analyses in LigAdvisor are provided in the download-
able tutorial in the ‘Help and tutorial’ section of the website
(available at: https://ligadvisor.unimore.it/tutorial), and in
the Supporting Material of this manuscript.
Single-query searches implemented in LigAdvisor
Single-query searches can be performed in LigAdvisor
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Figure 1. Statistics of ligand and target associations identified by similarity calculations on the LigAdvisor datasets. LigAdvisor includes data related to 28
415 and 10 767 unique ligands, extracted and curated from PDB and DrugBank databases, respectively. Similarity calculations performed on these curated
datasets collectively provided more than 2.5 million records (i.e. >1.5 mln similarities from the comparison of ligands curated from the PDB; >0.2 mln
similarities by ligands curated from the DrugBank, and; >0.9 from the comparison of PDB-curated ligands versus DrugBank compounds). Only similarity
records with MACCS and ECFP4 (Morgan) Tanimoto scores higher than 0.8 and 0.3 were retained, respectively. Interestingly, similarities computed across
the different databases provided similar trends, both in terms of MACCS (panel A) and ECFP4 (panel B). Moreover, as expected, the comparison of ligands
curated from the PDB provided higher numbers, both in terms of similarity and target associations records (panels C and D, respectively), compared to
the similarity estimations with those from DrugBank-related ligands. In LigAdvisor, targets are identified by means of their UniProt identifiers (>18 000
targets, mapped by PDB- and DrugBank-related compounds). Of note, several target associations resulted from the comparison of different datasets,
i.e. the same pair of targets emerged from both the comparison of PDB ligands and DrugBank compounds (panel D). Indeed, these target combinations
potentially represent the most valuable source for the development of polypharmacology ligands, as they are associated with crystallographic information
and related biological information from literature.
homepage, which allows users to retrieve information about
a specific drug, clinical or pre-clinical candidate, crystallo-
graphic ligand, target or therapeutic indication already in-
cluded in the curated database. Moreover, searches on cus-
tom molecular structures can also be performed through
this panel, by manually sketching them into a dedicated in-
put box. These types of searches are particularly useful for
users interested in target fishing, polypharmacology, drug
repurposing and off-target predictions.
Single-query similarity analyses can be performed within
the curated datasets by selecting different combinations of
MACCS and ECFP4 (Morgan) score thresholds (expressed
as percentage of Tanimoto similarity) to enable fine tuning
of the results. In addition, searches based on the presence of
substructures of interests are also implemented. LigAdvisor
accepts several types of ligand queries, including SMILES
identifiers and molecular structures drawn into a dedicated
input box implemented in the JMSE tool (27) (Figure 2A).
The ‘Search in LigAdvisor’ panel is designed to also al-
low users to query the database for a specific target or clin-
ical data of interest. In this case, target and clinical data
queries should be supplied to the webserver as target names,
UniProt IDs, or ClinicalTrials.gov identifiers (NCT num-
ber), into the dedicated input text box (Figure 2A).
The output of single-query searches provides a summary
page with statistics (i.e., the number of reported and similar
compounds for target and ligand queries, respectively), and
identifiers with hyperlinks to internal LigAdvisor pages, if
the queried compound is already included in the database
(Figure 3A). Similar ligands and confirmed targets are also
reported for compounds that are curated in the databases,
along with their similarity scores and statistics. For cus-
tom ligand searches, a list of structurally close compounds
is reported, along with their similarity scores. Selecting a
record from the resulting list returns information on the re-
lated ligand in the database, as previously described. Target-
based searches return information on the query target, to-
gether with a list of its associated crystallographic ligands,
clinically or pre-clinically investigated compounds and ap-
proved drugs. Finally, searches based on NCT identifiers
report information on clinical trials data, such as associ-
ated drugs identifiers and status of approval. This type of
search is particularly helpful for drug repositioning and tar-
get fishing, and to analyse target- and clinical-related data.
Remarkably, the single-query search implemented in Lig-
Advisor enables to query a large, high-quality dataset, com-
prising >30 000 unique ligands, 18 000 experimentally con-
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Figure 2. The three main LigAdvisor input search interfaces. Panel (A) reports the input interface of the ‘Single-query searches implemented in LigAdvisor’,
which is accessible through the web site homepage. Through this window, users can perform ligand- and target-based searches. In particular, ligand-based
searches can be performed by means of PDB and DrugBank identifiers, or SMILES. Moreover, molecular structures can also be drawn through a dedicated
input panel. Target-related information and clinical data can be queried by means of UniProt and NCT identifiers, respectively. Panel (B) shows the ‘Explore
ligands’ search interface, through which users can query the webserver for information related to a set of ligands. Further refinements of the multi-ligands
query can be applied to only retain information related to specific targets and/or clinical data. Panel (C) reports an example of the ‘Explore targets’ search
interface. Through this window, users can search for information related to similar ligands between pairs of selected targets.
of our knowledge, the number of records available from this
search is far higher than those of other databases and web-
servers focussing on drug repurposing and polypharmacol-
ogy.
The ‘Explore ligands’ search tab
The ‘Explore ligands’ search tab is designed to query the
webserver for data associated to multiple ligands simul-
taneously. This type of search is particularly useful, for
example, when a user is interested in identifying targets
potentially in common between a set of ligands, and re-
trieve their related clinical data. Indeed, ligands with sim-
ilar therapeutic effects may derive from similar biological
profiles (28). Moreover, this type of search is also suit-
able for target fishing and drug repurposing applications.
The queries can be selected directly via drug names, Drug-
Bank IDs and HET IDs of the investigated ligands (Fig-
ure 2B). Moreover, fully customizable ligand queries can
also be performed through their SMILES identifiers, by
typing them into an input text box, or by directly draw-
ing the molecules in the dedicated toolbox, as described
above. Multi-ligand queries in the ‘Explore ligands’ search
tab can also be refined to restrict the results on specific
subsets of targets and/or clinical data, thereby allowing
the user to focus on a particular therapeutic indication of
interest.
The output of ‘Explore ligands’ searches reports a list of
molecular targets, ligand similarities and clinical data, or-
ganized in tabs along with their statistics, to enable fast and
easy navigation across different data types in the database
(Figure 3B). The records in each tab (‘DrugBank’ and
‘PDB’) can be separately queried to analyse the informa-
tion associated to targets and ligands resulting from the
search. Confirmed targets and related clinical data for simi-
lar compounds are reported for searches on ligands curated
from DrugBank, while ligands in their complexes and co-
crystallized targets are reported for records related to PDB
ligands. The list of molecular targets resulting from this type
of search is ranked in descending order, according to the
number of reported similarity records. Indeed, targets with
the highest number of ligands in common are expected to
be more likely to share a wider overlapping chemical space,
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Figure 3. Examples of the results potentially obtainable by single- and multi-query searches implemented in LigAdvisor. In particular, panel (A) reports an
example of results obtained by means of the ligand-based single-query search. As shown, the result page first provides information on targets and ligands
identifiers across external databases. Clinical data is also reported, if present. Then, it reports a list of all drugs and clinical candidates (‘DrugBank’ tab),
and crystallographic compounds (‘Protein Data Bank’ tab) that resulted to be similar to the query, along with their MACCS and ECFP4 scores. Panel (B)
shows the results that can be visualized for the ‘Explore ligands’ multi-query search. In this case, overall statistics related to ligands similarities are reported
in the upper-left part of the page. Moreover, ligands- and targets-related records are also reported as lists at the bottom of the page, the selection of each
record allowing users to access to its specific information. Panel (C) reports the results of the ‘Explore targets’ search. In particular, the overall statistics
of similarities observed between ligands of the selected targets and involvement in common pathways are reported in the upper-left part of the page, while
a graphical representation of the similarity score distributions is shown in the upper-right corner. The observed ligand similarities are listed according
to datasets comparison. By clicking on each similarity record in the tabs, users can visually inspect the chemical structures of related ligands. Moreover,
records related to shared biological pathways between the targets of interest are also reported (‘Common pathways’ tab).
proach. Moreover, they also have the highest probability to
be the most suitable targets for drug repositioning and tar-
get fishing.
The ‘Explore Targets Combinations’ search tab
Searches performed through the ‘Explore Targets Combi-
nations’ tab allow users to compare the chemical spaces
covered by ligands reported within the database, for pairs
of targets of interest. This type of search is expected to
help identify novel potential multi-target ligands, based on
the concept that structurally similar compounds could have
similar biological activities (29). These results could also be
useful to identify the more suitable protein conformation(s)
for subsequent structure-based in silico polypharmacology











alavasi user on 23 August 2021
W332 Nucleic Acids Research, 2021, Vol. 49, Web Server issue
queried through their UniProt identifiers or names via a
drop-down menu, which was designed to dynamically re-
strict the search upon the keyword typed in the dedicated
input text box (Figure 2C).
The search returns statistics related to the targets of in-
terests, both in terms of retrieved number of similar com-
pounds above threshold, and involvement in shared bio-
logical pathways according to TTD data (21). Moreover,
a graphical representation of the similarity distribution of
compounds is also reported (Figure 3C). Results of the
‘Explore Targets Combinations’ search are organized in dif-
ferent tabs, i.e. comparison of ligands curated only from
PDB (reported in the ‘PDB vs PDB’ tab), comparison of
PDB versus DrugBank molecules (‘PDB vs DrugBank’) and
comparison of DrugBank compounds (‘DrugBank vs Drug-
Bank’). In each tab, a list of compound pairs emerging from
similarity analyses, sorted by descending ECFP4 (Morgan
Fingerprint) score, is reported. By selecting (clicking on)
any row, the user can visually inspect the chemical struc-
tures of the related ligand pairs. Moreover, the occurrence of
any shared biological pathways for the selected target pair is
also reported in the ‘Common pathways’ tab. We added this
latter section into the ‘Explore Targets Combinations’ multi-
query search to facilitate users in identifying target pairs of
potentially higher therapeutic interest.
Results obtained from the different searches can be col-
lectively downloaded as .txt and .json files to facilitate post-
processing analyses by both high-qualified and non-expert
users on local devices. Moreover, the results reported into
different tabs can also be separately downloaded as a .csv
files for more focussed investigations.
LigAdvisor and current webservers for drug repurposing and
polypharmacology
In this section, we will provide the reader with an overview
of available servers in the field of repurposing and polyphar-
macology, and how LigAdvisor fits into this context.
Currently, other databases specifically focussing on
drugs, their therapeutic indications, bioactivity data and
drug–target interactions have been reported to facilitate
drug repurposing (8,9,11,12) (Supplementary Table S1).
For example, the ReframeDB (8) and repoDB portals (12)
provide information on around 12 000 compounds collected
from published journals and patents with disease anno-
tations. While these resources enable ligand repurposing
through their similarity with known drugs, results can re-
quire further processing to be efficiently exploited. On the
contrary, LigAdvisor provides direct annotations on more
than 18 000 targets, from 28 415 PDB and 10 767 Drug-
Bank unique ligands, resulting in a far higher number of
ligand-targets associations with respect to current databases
of repurposed drugs. Repurposing-related webservers en-
trusting on larger datasets of ligands are also reported. For
example, the MuSSel website (30) facilitates the identifica-
tion of novel putative targets for small molecules, based on
the similarity with ChEMBL compounds. Moreover, the
Promiscuous 2.0 webserver (31), which provides access to
a huge reservoir of well-organised and integrated informa-
tion, has also been recently helping scientists in drug repo-
sitioning and profiling tasks. The possibility to exploit such
larger databases would certainly provide higher chances of
repositioning for the compounds. However, the presence
of potential false positive compounds on larger databases
of bioactivity data should not be neglected. Indeed, re-
sults can often differ upon the adopted experimental con-
ditions in the assays, making their mechanism of action
not fully interpretable (32). One key strength of LigAdvi-
sor in this regard is the ability to provide links to the 3D
structural information available from ligand-protein com-
plexes in the PDB. This is expected to facilitate the iden-
tification of how ligands bind to their novel putative tar-
gets. The ability to perform multi-query searches is another
key asset of LigAdvisor for drug repurposing, especially
when multiple compounds belonging to the same family
scaffold have to be investigated. Notably, this functionality
has never been embedded in a webserver focussing on drug
repurposing and polypharmacology. Other repurposing-
related webservers include the Drug ReposER portal (33)
and PharmMapper (34), which enable the repurposing of
compounds through the sub-structural similarity between
the binding site interfaces of known drugs in their targets
and pharmacophore mapping, respectively. Although these
webtools provide valuable approaches to repurpose com-
pounds towards novel drug targets, many of them rely on
smaller datasets or do not allow a direct integration of their
results with clinical data, as opposed to LigAdvisor. Pro-
grams and webservers developed to facilitate the identifica-
tion of targets for ligands according to binding site align-
ment, or on the similarity of: (i) molecular structures; (ii)
ligand-protein interactions patterns, and; (iii) residue se-
quences have also been recently reported (35–38). These
webservers would represent valuable complementary tools
to integrate for drug repurposing and polypharmacology,
although their results very often require further process-
ing to be fully exploited. Similar considerations can also be
drawn for webservers specifically focussing on multi-target
drug design or polypharmacology profiling (10,39). These
include, for example, the Polypharma webserver (39), which
allows to depict the putative polypharmacological profile of
molecules by means of their similarity with crystallographic
ligands, although their analyses are focused on single ligand
or target queries, and do not provide clinical data informa-
tion. Finally, web portals that provide drug combinations
experimentally studied, such as DrugComb (40), are also
published. Although these latter databases provide infor-
mation of high interest for the development of multi-target
ligands, they are very often focussed on cancer research. On
the contrary, LigAdvisor can provide information on com-
mon pathways and mutual involvement on a wide range of
diseases for any given pair of targets, thanks to its integra-
tion with TTD data. This information is of high value for
both polypharmacology de novo design and profiling.
CASE STUDIES
Information and examples on the different types of searches
that can be performed with LigAdvisor are provided in the
website (https://ligadvisor.unimore.it/tutorial, accessed on
17 April 2021), and Supporting Material. The tutorial in-
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query searches implemented in LigAdvisor, through a series
of dedicated examples.
In particular, the reader will be provided with repre-
sentative ligand- and target-based case studies, which help
in demonstrating how LigAdvisor can be used to facili-
tate polypharmacology and drug repositioning tasks. To
this aim, validated target-disease associations were first ex-
tracted from the Therapeutic Target Database (TTD) (ac-
cessed on 6 March 2021) (21), and then integrated with in-
formation related to targets from the UniProt (20) database
and similarity data from LigAdvisor. The analyses were
focussed on 34 therapeutic indications, each associated
with >10 different targets. A list of the investigated indi-
cations, along with their molecular targets is reported in
Supplementary Table S2 (see the Supplementary Material).
Data from LigAdvisor was filtered to retain only similar-
ity records for ligands with confirmed activity on targets
related to the same TTD disease indication. This allowed
to identify 680 target associations across the selected 34
therapeutic indications. We are aware that not all identi-
fied target associations with pairs of structurally related
ligands may have a therapeutic significance in the selected
disease indications. Thus, a close analysis of the obtained
data allowed the identification of target pairs that gave ex-
cellent levels of similarity. These pairs of targets represent
valuable starting points for the design of multi-target lig-
ands. Hereafter, two of the identified associations will be
discussed in detail for such purpose. A first example selected
among the obtained pairs comes from the association of two
cancer related targets, i.e., Heat shock protein 90 (Hsp90,
UniProt ID: P07900) and the JAK2 Tyrosine-protein ki-
nase (UniProt ID: O60674), which have been previously val-
idated as a potential synergistic combination for the treat-
ment of different tumour types (41–43). Interestingly, this
pair of targets provided 31 similarity records from 27 Hsp90
ligands and 17 JAK2 compounds, belonging to different
chemotypes and known binding mode (see Supplementary
Table S3 in the Supporting Material). Among the identified
pairs of Hsp90- and JAK2-ligands, an example of partic-
ular interest comes from the comparison of the crystallo-
graphic compounds with HET IDs 73S (in complex with
Hsp90, PDB code 5LRL, DOI: 10.2210/pdb5LRL/pdb)
and VVQ (crystallized with JAK2, PDB code: 4D0W) (44),
which provided similarity scores of 0.884 (MACCS) and
0.238 (ECFP4). Supplementary Figure S1 highlights the 2D
structure of the selected pair of ligands, and the experimen-
tally observed binding mode in their respective targets. In-
terestingly, both compounds present a 2-amino-pyrimidine
core scaffold through which they interact with key residues
in the Hsp90 and JAK2 proteins (i.e., Asp93, and Glu930
and Leu932, respectively). Indeed, these residues are often
engaged in H-bond interactions with Hsp90 and JAK2 se-
lective inhibitors, thus representing valuable common an-
choring points for the development of dual ligands. The
possibility to exploit common anchoring points and sub-
structures provides advantages in the development of multi-
target ligands, as they facilitate the integration of the dif-
ferent structural requirements of the targets of interest into
a single drug-like entity. This is particularly useful for the
design of compounds acting on targets that belong to dif-
ferent protein families, such as JAK2 and Hsp90, for which
ligands with balanced dual activity have not been reported
yet. Similar considerations can also be drawn for the asso-
ciation of progesterone receptor (UniProt ID: P06401) and
the aromatase enzyme (UniProt ID: P11511), for which re-
cent findings demonstrated that their combined inhibition
provides improved efficacy in the treatment of endometrio-
sis (45,46). To evaluate whether this association could rep-
resent a valuable starting point for the development of dual
ligands, we performed target-based searches in LigAdvisor,
identifying significant similarities (see Supplementary Table
S4 in the Supplementary Material), especially among their
known drugs or crystallographic compounds. Notably, sev-
eral scaffolds of the compounds in the identified pairs (see
Supplementary Figure S2 in the Supplementary Material)
have already been clinically investigated and may provide
clues on the structural requirements for the development of
potential multi-target ligands.
Finally, we report another application of our webserver
related to Alzheimer’s disease (AD), for which drug repo-
sitioning campaigns are currently being pursued (47). To
this aim, we first extracted a list of 22 potential repur-
posing candidates that are under clinical investigation for
AD, as recently reported by Jordan et al. (48), and as-
sociated to their respective DrugBank identifiers. Then, a
series of analyses were performed on each of the investi-
gated drug, through the ligand-based single-query search
approach implemented in LigAdvisor. This allowed us to
obtain a subset of structurally similar ligands, with their
experimentally confirmed targets. Afterwards, the informa-
tion related to molecular targets identified for these drugs
was integrated with disease associations reported in TTD.
This allowed us to evaluate whether LigAdvisor was able
to retrieve therapeutic targets associated to AD. Notably,
8 of the 22 investigated drugs were associated to at least
one target related to Alzheimer’s disease (see Supplemen-
tary Table S5 in the Supplementary Material), according to
LigAdvisor predictions. Moreover, six of these drugs were
also associated to AD-related targets, for which their ac-
tivity has yet to be experimentally confirmed. These lat-
ter associations are particularly appealing and may help in
unveiling new potential targets for already known drugs.
An example among the identified compounds comes from
DB1166 (cilostazol), which was originally approved in 1999
as a PDE3 inhibitor (49). Interestingly, cilostazol demon-
strated to have positive effects in attenuating cognitive de-
cline (50), although its biomolecular mechanism of action
has not been fully elucidated yet. The analyses performed
in LigAdvisor associated cilostazol to several AD-related
targets reported in TTD, i.e., Muscarinic acetylcholine re-
ceptor M1 (UniProt ID: P11229), D(4) dopamine recep-
tor (UniProt ID: P21917), 5-hydroxytryptamine receptor
2A (UniProt ID: P28223), Sodium-dependent serotonin
transporter (UniProt ID: P31645), D(3) dopamine receptor
(UniProt ID: P35462), cAMP-specific 3’,5’-cyclic phospho-
diesterase 4D (UniProt ID: Q08499) and Glutamate recep-
tor ionotropic NMDA 2A (UniProt ID: Q12879), suggest-
ing the possibility that this drug may act through polyphar-
macological mechanisms.
The examples reported above represent only part of the
functionalities offered by LigAdvisor. As a final note, Lig-
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formation(s) for structure-based multi-target calculations,
and help target fishing tasks.
CONCLUSIONS
Herein we have presented LigAdvisor, an intuitive and user-
friendly web platform that combines 2D chemical similar-
ity estimations on high quality sets of ligands curated from
DrugBank and PDB, and integrates it with information on
targets and clinical data reported in the UniProt, TTD and
ClinicalTrials.gov databases. LigAdvisor aims at facilitating
the combination of chemical, biological, structural and clin-
ical information reported for known ligands through an in-
tuitive interface, and to assist users in a variety of drug de-
sign tasks, including target fishing, polypharmacology de-
sign and drug repurposing. LigAdvisor is designed to per-
form searches on a large, high quality database of ligands
with reported clinical and preclinical information, as well as
crystallographic data. Indeed, the single-query and multi-
query searches implemented in LigAdvisor allow users to
navigate through a large, high-quality dataset including >30
000 unique ligands, 18 000 experimentally validated targets,
and 350 000 clinical data record. Notably, LigAdvisor is
the first webserver that enables searches per combination
of ligands and targets, to facilitate multi-target drug design
and drug repurposing. Further efforts will be addressed to
expand the chemical space of LigAdvisor, for example, by
including libraries of natural products, which represent a
valuable source of information for drug discovery (51).
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